Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Keros Therapeutics's current 1-Year Share Buyback Ratio was 51.20%.
KROS's 1-Year Share Buyback Ratio is ranked better than 99.64% of 1107
companies
in the Biotechnology industry
Industry Median: -14.1
vs KROS: 51.20
Keros Therapeutics (NAS:KROS) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Keros Therapeutics 1-Year Share Buyback Ratio Related Terms
KROS vs VYGR, CHRS, DTIL: 1-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Keros Therapeutics's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keros Therapeutics 1-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keros Therapeutics's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Keros Therapeutics's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of 51.20 mean?
Keros Therapeutics (KROS) has a 1-Year Share Buyback Ratio of 51.20 as of Jun. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Keros Therapeutics and its competitors. According to the industry distribution chart, Keros Therapeutics ranks #4 out of 1107 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is Keros Therapeutics' 1-Year Share Buyback Ratio too high?
Keros Therapeutics' current 1-Year Share Buyback Ratio is 51.20. Based on the distribution chart, Keros Therapeutics ranks #4 out of 1107 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Keros Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' 1-Year Share Buyback Ratio compare to VYGR and CHRS?
According to the Biotechnology industry distribution chart, Keros Therapeutics ranks #4 out of 1107 companies for 1-Year Share Buyback Ratio. This places Keros Therapeutics in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Keros Therapeutics and its competitors. Keros Therapeutics's current 1-Year Share Buyback Ratio is 51.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Keros Therapeutics (KROS) is currently considered Fairly Valued. The stock's GF Value™ is $10.10, compared to a current price of $11.10 — trading 9.9% above its estimated fair value. The current 1-Year Share Buyback Ratio is 51.20. Keros Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current 1-Year Share Buyback Ratio is 51.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Keros Therapeutics (KROS) Overvalued in 2026?
Based on GuruFocus' analysis, Keros Therapeutics stock appears to be overvalued.
The current stock price of $11.10 is trading 9.9% above its estimated GF Value™ of $10.10.
GuruFocus considers Keros Therapeutics to be Fairly Valued.
Key valuation signals for KROS:
1-Year Share Buyback Ratio: 51.20
GF Value™: $10.10 vs. price of $11.10 (9.9% above fair value)
No single metric tells the full story. See the KROS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
52GF Score
Get the complete analysis for KROS
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KROS has been successfully added to your 
